Redeye initates coverage on NeuroVive

Redeye initiates coverage of NeuroVive, a high-risk case with a promising early-stage portfolio in primary mitochondrial diseases. While previous high-profile failures and dilutive rights issues have hurt the company’s standing, the share’s huge decline has taken valuation to undemanding levels – though nearer-term catalysts are few and the current capital raising may weigh on performance.

Read more and download the research update: http://bit.ly/NeuroVive
Start following companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. https://www.redeye.se/about/